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Gender Differences in Local and Systemic Reactions 
to Inactivated Influenza Vaccine, Established by a 
Meta-Analysis of Fourteen Independent Studies 
W.E.E  Beyer  1, A .M.  Pa lache  1, R .  Kers tens  2, N. Masure l  1.  
In order to determine whether there is a difference between genders in reported adverse 
reactions to inactivated influenza vaccine, a computerized database of serological stud- 
ies was investigated. A standardized questionnaire was used to evaluate vaccine reac- 
togenicity. A total of 1,800 vaccinees in 14 studies were analyzed separately for two age 
groups (< 60 and __ 60 years of age). Females reported significantly more local reac- 
tions than males. The pooled odds ratio for the outcome measure "any local reaction" 
was 0.32 (95% confidence interval, 0.26-0.40, significant) and 0.54 (95% CI, 0.41-0.70, 
significant) for young and elderly adults, respectively. Similar results were obtained for 
the outcome measure "any systemic reaction." Previous exposure to influenza or influen- 
za vaccine had no influence on reactogenicity. There were no gender differences in sero- 
responses. In conclusion, gender should be regarded as a predictor of reported reac- 
tions to influenza vaccine in both young and elderly adults and should be addressed in 
future study designs. 
Possible differences between drug action in men 
and women have recently caused growing concern 
in clinical and pharmacological research. In 1993 
the U.S. Food and Drug Administration issued 
new guidelines to stimulate the inclusion of more 
women in clinical trials and to analyze clinical 
data by sex (1). 
The nature of reactions and side-effects after in- 
activated whole-virus, split, or subunit influenza 
vaccines is generally mild and transitory (2). 
Even if a difference in reactogenicity between the 
sexes existed, it would have little clinical meaning. 
In scientific research, however, a difference be- 
tween the genders, if not addressed, could be a rel- 
evant source of error when comparing reactoge- 
nicity of different vaccine types, dosages, or ad- 
ministration regimens. 
Some earlier papers suggested that the incidence 
of local or systemic reactions after influenza vac- 
cination was higher in adult females than in adult 
males (3-7). However, two of these studies (3, 5) 
used the influenza AfNew Jersey/76 (HIN1) 
swine strain, which showed unusual characteristics 
of reactogenicity. In two other reports (4, 7), 
data on gender differences were presented as an 
accidental finding, and one investigation (6) had 
only small study groups. 
In an attempt to substantiate a possible difference 
between genders in vaccine reactogenicity, we 
analyzed computerized data on reported reactions 
from trials with an influenza subunit vaccine per- 
formed during a ten-year period. In these trials 
the same standardized questionnaire to evaluate 
reactions had been used. Data on prevaccination 
status (vaccinations in previous years, and prevac- 
cination serology) and seroresponse to the vaccine 
were also analyzed. 
Materials and Methods 
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Sources of Data and Study Design. In the period 1982-1991, 
30 serological studies with influenza subunit vaccine (Solvay 
Duphar, The Netherlands) were conducted for registration 
purposes. All studies were performed according to standard 
operating procedures tocomply with the Dutch Good Clini- 
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Table 1: Numbers of subjects for meta-analysis (MA) of reported reactions. 
Age MA Study Hema- No. of No. of No. of Any Any 
group group no. a glutinin subjects females males local systemic 
dose (IJg) symptom symptom 
Incon- 
venience b
Young 1 1 30 116 66 50 56 26 9 
2 4 30 125 24 101 39 15 5 
3 7 30 85 44 41 34 20 6 
4 9 30 101 49 52 27 23 6 
5 11 30 69 42 27 31 16 4 
6 11 60 71 43 28 36 18 7 
7 15 30 122 70 52 35 16 2 
8 18 30 148 85 63 62 38 3 
9 19 c 30 41 19 22 28 5 0 
10 21 30 70 39 31 31 19 4 
11 21 60 71 39 31 36 12 5 
12 22 30 72 30 42 35 15 3 
13 22 45 72 43 29 45 15 6 
14 22 60 72 30 42 40 17 3 
15 24 30 100 32 68 24 14 4 
16 28 30 99 51 48 43 18 4 
Elderly 17 17 30 114 55 59 38 19 7 
18 19 c 30 139 71 68 63 40 13 
19 25 30 113 59 54 42 32 9 
aAccording to reference 9. 
b Number reporting. 
c Study 19 was subdivided into two meta-analysis groups, according to subjects' age. 
cal Practice guidelines, after obtaining ethics committee ap- 
proval. One study was a multicentre, randomized, placebo- 
controlled ouble-blind study recently published (8); the oth- 
er studies have not been published. However, an overview of 
all of these studies has been published (9). Study participants 
were either young healthy volunteers ecruited from medical 
teaching institutions, ubjects of all ages visiting eneral prac- 
tices, or residents of nursing homes. 
The study procedures were virtually identical for all studies. 
Briefly, before vaccination, volunteers were interviewed to 
obtain their history of previous vaccinations and to exclude 
those with a known allergy to chicken proteins. Suitable sub- 
jects were asked to give written informed consent. A prevac- 
cination blood sample was taken, and 0.5 ml of vaccine was 
then administered intramuscularly. A second blood sample 
was taken two to four weeks after vaccination. Homologous 
antibody titres of blood samples were determined by stan- 
dard hemagglutination-inhibition tests (10-12). Further de- 
tails on study designs, sizes, vaccine composition, and dos- 
ages have been published previously (9). 
In the studies in which data on reactogenicity were collected, 
each volunteer received a standard questionnaire onwhich to 
report adverse ffects during the 48 h period following vacci- 
nation. Questionnaire forms were distributed on the day of 
vaccination and were collected when the second blood sam- 
ple was drawn. The questionnaire addressed seven local and 
five systemic symptoms, as well as the degree of inconven- 
ience these symptoms caused. Local reactions included red- 
ness, swelling, itching, warmth, pain on contact or continuous 
pain at the site of vaccination, and restriction in arm move- 
ment. Systemic reactions included fever, increased sweating, 
headache, malaise, and insomnia. Inconvenience was record- 
ed as absent, slight, moderate, or severe. Afterwards, two ad- 
ditional summary variables were derived: "any local reac- 
tion" and "any systemic reaction." 
Selection of Data. Dosages used in the trials varied from 0 to 
180 p~g hemagglutinin (total amount of hemagglutinin for all 
virus strains). Most trials were single-dose experiments, and 
some were dose-response studies. Most common was a dose 
of 30 Ixg hemagglutinin (trivalent vaccine with 10 ~g hemag- 
glutinin per strain). For the present analysis, a dose range of 
30 to 60 txg hemagglutinin was chosen because this interval 
corresponds to the total amount of hemagglutinin in current 
vaccines (trivalent or tetravalent vaccines with 10 or 15 txg he- 
magglutinin per strain). If a trial included more than one 
dose, dose groups were analyzed separately. Subjects < 60 
years of age ("young") and subjects _> 60 years of age ("eld- 
erly") were analyzed separately. Meta-analysis groups were 
formed according to trial, dosage, and age. 
Statistical Procedures. The data of all groups in the meta-anal- 
ysis were arranged in 2*2 matrix tables (presence and absence 
of reaction vs. males and females) and subjected to a homo- 
geneity test between meta-analysis groups according to 
Breslow and Day (13). If homogeneity could be confirmed, 
the Cochran-Mantel-Haenzel method of meta-analysis, as
modified by Yusuf et al. (14), was applied, resulting in pooled 
odds ratios and their 95% confidence intervals (CIs). In the 
case of no difference between the sexes, the pooled odds ra- 
tio value is 1. A pooled odds ratio less than 1 means that the 
frequency of a reaction in females i higher than in males, and 
vice versa. Using the same procedure, reactions versus dos- 
age, previous vaccination, and prevaccination a tibody status, 
and seroresponse variables versus gender were subjected to 
meta-analysis. 
Results 
Definite Number of Subjects for Analysis, and 
Overall Frequency of Reactions. Of  the  30 sero log-  
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Figure 1: Frequencies of reported vaccine reactions, according to meta-analysis groups and gender. 1A: any local symptom 
reported; 1 B: any systemic symptom reported. * represents significant difference between males and females. 
ical studies performed between 1982 and 1991 (9), 
15 studies (with 2,267 subjects) included registra- 
tion of adverse reactions. In one of these studies 
(with 115 elderly subjects, most of whom suffered 
from dementia) virtually no reactions were report- 
ed; this study was excluded. Of the remaining vac- 
cinees, 352 were vaccinated with doses of less than 
30 txg or greater than 60 ~g hemagglutinin, and 
these were also excluded. Thus, the individual da- 
ta of 1,800 subjects from 14 studies could be in- 
cluded, consisting of 1,434 young adults (range 16 
to 59 years of age, mean 24.9) and 366 elderly (62 
to 94 years of age, mean 74.7). Subjects were di- 
vided into 19 meta-analysis groups (Table 1). 
Of the local reactions, pain on contact was report- 
ed most frequently; of systemic reactions, head- 
ache. Data on inconvenience w re included as ei- 
ther moderate or severe; these latter numbers 
were small in all studies, confirming the general- 
ly mild nature of vaccine reactions. There were 
large differences between the meta-analysis 
groups in the frequencies of reactions reported: 
for example, in meta-analysis group 9, 68.3% of 
the vaccines reported "any local reaction," com- 
pared to only 26.7% in meta-analysis group 4. 
Influence of Gender on Frequency of Reactions. 
For every single reaction, the frequency and odds 
ratio per meta-analysis group were calculated. As 
an example, Figure 1 presents results for "any lo- 
cal reaction" and "any systemic reaction." A sig- 
nificantly higher frequency of "any local reaction" 
in females than in males was detected in 13 of the 
19 meta-analysis groups. For "any systemic reac- 
tion," only meta-analysis groups 7 and 8 showed 
a significant difference between the sexes. 
The test on homogeneity indicated the presence 
of homogeneity for all reactions in both age 
groups (data not shown). Table 2 presents the 
pooled odds ratios per symptom. In the young 
adults, a clear difference between genders was 
present for each of the local reactions: all seven 
pooled odds ratio values were less than 1, reach- 
ing a significant level in six groups. The pooled 
odds ratio for "any local reaction" was also signif- 
icant: 0.32 (95% CI: 0.26-0.40). A gender differ- 
ence for systemic reactions was present, although 
less pronounced. Pooled odds ratio values were 
generally greater for systemic than for local reac- 
tions but were still significantly less than 1 for 
"sweating," "headache," and "any systemic reac- 
tion"; the symptom "fever" may be a borderline 
case. Two systemic reactions, "malaise" and "in- 
somnia," were associated with pooled odds ratio 
values close to 1, thus showing no gender differ- 
ence. Finally, significantly more women suffered 
from moderate or severe inconvenience. 
A gender difference for local reactions was also 
observed in the elderly. Pooled odds ratio values 
for all seven reactions and for "any local reaction" 
were less than 1. Only the values for "itching" and 
"warmth" did not reach a significant level. The 
systemic reactions "sweating" and "malaise" 
scored lower than in the young adults, whereas 
"fever" and "headache" scored higher. The score 
for "moderate orsevere inconvenience" was very 
similar to that of the young age group. 
There was one unexpected difference between the 
age groups: "insomnia" was gender neutral in 
young adults but was found to be significantly 
more frequent in elderly males than in females. As 
a consequence, the summary variable "any system- 
ic reaction" showed a high and nonsignificant 
pooled odds ratio (0.67, 95% CI: 0.42-1.08) in the 
elderly. When "any systemic reaction" was recal- 
culated without he symptom "insomnia" (in Ta- 
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Table 2" Pooled odd ratios (POR) of gender dif ferences for  vaccine reactions in young and elderly vac-  
cinees. 
Vaccine reaction POR young a POR elderly a 
Redness 0.30 (0.22 - 0.43) + 0.29 (0.15 - 0.54) + 
Swell ing 0.32 (0 .22-  0.46) + 0.31 (0 .17-  0.60) + 
Itching 0.33 (0.19 - 0.57) + 0.69 (0.36 - 1.34) - 
Warmth 0.31 (0.22 - 0.44) + 0.54 (0.28 - 1.05) - 
Pain on contact  0.36 (0.28 - 0.45) + 0.43 (0.26 - 0.71) + 
Cont inuous pain 0.70 (0.43 - 1.12) - 0.21 (0.06 - 0.83) + 
Restr icted arm movement  0.42 (0.28 - 0.65) + 0.45 (0.21 - 0.96) + 
Fever 0.57 (0.32 - 1.00) - 0.89 (0.34 - 2.33) - 
Increased sweat ing 0.55 (0.34 - 0.88) + 0.33 (0.14 - 0.77) + 
Headache 0.42 (0.30 - 0.59) + 0.70 (0.39 - 1.26) - 
Malaise 0.97 (0.61 - 1.52) - 0.43 (0.21 - 0.91) + 
Insomnia 0.92 (0.52 - 1.63) - 2.95 (1.29 - 6.74) + 
Inconvenience b 0.36 (0.22 - 0.59) + 0.39 (0.18 - 0.84) + 
Any local reaction 0.32 
Any systemic reaction 0.54 
Any systemic reaction after correct ion c 0.51 
(0.26 - 0.40) + 0.54 (0.35 - 0.82) + 
(0.41 - 0.70) + 0.67 (0.42 - 1.08) - 
(0.39 - 0.67) + 0.57 (0.35 - 0.94) + 
a Pooled odds  ratios with 95% conf idence intervals and signif icance (+, signif icant; -, not significant; 
at the 5% level). 
b Moderate  or severe inconvenience. 
c "Any systemic reaction," calculated wi thout  the symptom " insomnia" (see text). 
ble 2, "any systemic reaction corrected"), the 
pooled odds ratio became significant in the elder- 
ly and was similar to that of young adults (0.57, 
95% CI: 0.35-0.94). 
Influence of Dose, Previous Vaccinations, and Pre- 
Vaccination Antibody Status on Frequency of Re- 
actions. Three studies including 425 subjects 
(studies 11, 21, and 22; Table 1) allowed a compar- 
ison of reactions for doses of 30 and 60 Ixg hemag- 
glutinin by a similar procedure of meta-analysis 
(not shown). There was no dose-response relation- 
ship for systemic reactions, but two single local re- 
actions (swelling, continuous pain) were reported 
more frequently in vaccinees who received the 
higher dosage. 
Data were analyzed for the influence of vaccina- 
tions against influenza in previous years. For all 
reactions, no differences were detected between 
subjects previously vaccinated and those not pre- 
viously vaccinated ( ata not shown). Reaction fre- 
quencies were analyzed according to the prevac- 
cination antibody status (seronegative s.seropos- 
itive, and not protected vs. protected, prior to 
vaccination), separately for the three virus 
(sub)types. Prevaccination status had no influence 
on reactogenicity n any case (data not shown). 
Influence of Gender on Serological Variables. 
Quantitative and dichotomous serological vari- 
ables (geometric mean titres, and percentages of 
subjects exceeding protective threshold titres, 
prior to and after vaccination) were calculated ac- 
cording to gender (data not shown) and were 
found to be similar for males and females. There 
was no relationship between gender and serores- 
ponse in our data. 
Discussion 
Despite the use of a standard questionnaire, 
trials differed considerably in the frequency of re- 
ported reactions (Table 1). These inter-trial differ- 
ences were probably due to differences in the at- 
titude of researchers and vaccinees. Our trials 
were conducted in different study centres and by 
different researchers, and vaccinees differed in 
their educational nd social background. Some 
studies reporting very high reactogenicity were 
conducted inmedical students who were obvious- 
ly highly motivated to observe ven the slightest 
symptom. On the other hand, trials in the elderly 
may easily underreport eactions due to demen- 
tia and forgetfulness in the subjects. The criteri- 
on "age" may, therefore, measure not only immu- 
nological differences due to biological age but 
also psychological, mental, and medical differenc- 
es. Therefore, the two age groups were analyzed 
separately. It could thus be shown here that there 
were no essential differences between age groups. 
It is well known that those persons previously un- 
exposed to influenza (sub)types (unprimed sub- 
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jects) suffer from more reactions than those pre- 
viously exposed [for example, young adults vac- 
cinated in 1976 with the A/New Jersey/76 
(HIN1) swine strain (3, 5), young adults vaccinat- 
ed in 1977 with the A/USSR/77 (H1N1) strain 
(15), or young children vaccinated with any in- 
fluenza subtype (2)]. The populations inthe trials 
presented here consisted of adults, and the trials 
were performed between 1982 and 1991, i.e. dur- 
ing an interpandemic period, and did not include 
the NJ/76-strain. It could be assumed that virtu- 
ally all participants had already been exposed to 
natural influenza (sub)types A-H3N2, A-H1N1, 
and B. Indeed, a history of previous vaccinations 
and an antibody-status report required prior to 
vaccination were found not to influence the fre- 
quency of reactions. 
Published reports how a dose-response relation- 
ship for local reactions and, though less pro- 
nounced, for systemic reactions (6, 8, 16-19). We 
controlled possible dose bias by dividing studies 
with different doses into separate groups. We 
confirmed that a higher dose (60 vs. 30 txg hemag- 
glutinin) was associated with a higher frequency 
of some local reactions. 
During the period 1982 to 1991, the industrial 
manufacture of the subunit vaccine used was 
based on the procedure of Bachmayer et al. (20) 
and had not been modified. The strain composi- 
tion of the vaccines, however, changed every year 
(see Table 2 of reference 9). It is conceivable that 
certain influenza strains could be more reactogen- 
ic than others, which may have contributed tothe 
heterogeneity between studies. 
After applying amethod of meta-analysis, gender 
differences were established for both local and sys- 
temic reactions and for both age classes: female 
vaccinees reported more reactions than male 
vaccinees (Table 2). Moreover, ahistory of previ- 
ous vaccinations did not influence reported reac- 
tions. These two results are in good accordance 
with a large single vaccination trial by Govaert et 
al. (7), who applied a similar method of data as- 
sessment in a large study group (1,806 partici- 
pants). The only difference was that they also 
found a significantly higher frequency of females 
reporting "any systemic reaction," something we 
did not observe. This may be due to our inclusion 
of the symptom "insomnia" in our questionnaire, 
which was not included by Govaert et al. (7). 
After correcting for this possibly untypical 
symptom, we found our results to be similar to 
theirs. 
When interpreting the results of our study, one 
should keep in mind that data on reactions were 
not collected by a physician when symptoms oc- 
curred but were reported by the vaccinees them- 
selves. The data do not represent actual reactions 
but the frequency of vaccine reactions reported 
and may, therefore, be influenced by individual 
mechanisms such as understatement a d exagger- 
ation, i.e. by gender-specific, psychological rather 
than physiological factors. The concept that vac- 
cine reactions may be mediated by physiological 
gender differences can be neither denied nor 
supported by our data. It is, however, emarkable 
that fever, the most "objective" reaction, was not 
found for a clear gender difference, again in ac- 
cordance with the study of Govaert et al. (7). Re- 
ports in the field of medical psychology have doc- 
umented gender differences in the awareness of 
perception of pain (21-24). 
In conclusion, our data suggest that gender is a 
predictor of reported influenza vaccine reactions 
in young and elderly adults. We recommend, 
therefore, that groups with similar numbers of fe- 
males and males be studied when investigating 
vaccine reactogenicity, and that gender be includ- 
ed as an independent variable in the statistical 
analysis. 
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